Objective:

To evaluate the efficacy of an individualized cancer vaccine, TG4050, in preventing disease recurrence in patients with resected, human papillomavirus-negative head and neck squamous cell carcinoma.

Approach:

• Trial Design: A small randomized trial where patients were assigned to receive the investigational vaccine after standard adjuvant therapy or to undergo watchful waiting.
• Vaccine Development: TG4050 is personalized for each patient using tumor and normal tissue samples to identify cancer-specific mutations, with an AI system selecting neoantigens for immune targeting.

Key Findings:

• All 16 patients treated with TG4050 remained disease-free after a median follow-up of 41 months.
• Three of the 16 patients in the control group experienced disease recurrence after a median follow-up of 30 months.
• The vaccine induced detectable T-cell responses in 73.3% of evaluated patients, with responses persisting over a year after the final dose.
• No unexpected safety findings were reported during long-term follow-up.

Interpretation:

The results suggest that TG4050 may effectively prevent disease recurrence in this patient population.

Limitations:

• The trial involved a small sample size.
• The study's findings are based on a median follow-up of 41 months, which may not capture long-term outcomes.

Conclusion:

A larger randomized phase II study is underway to further evaluate immune responses and disease-free survival.

Sources:

• Transgene and NEC Report